Korea Research Institute of Chemical Technology

Snu Rdb Foundation

Jeong-Ho Hong

Jung Nyoung Heo

Sung-Eun Yoo

Kyu Yang Yi

Jee Hee Suh

Sung Youn Chang

Nak Jeong Kim

Eun Sook Hwang

Myung-Ae Bae

Namsook Kang

Jae-Hwan Lee

Jung-Rae Rho

Chan-Soo Shin

Eun-O Kim

Seung-Bum Park

Jun-Young Hong

Jeong-Ah Kim

Sang-Mi Oh

Heon-Joong Kang

A pharmaceutical composition comprising a phenyltetrazole derivative of formula (I) or a pharmaceutical acceptable salt thereof is effective in preventing or treating osteoporosis, obesity, diabetes, or hyperlipidemia, by regulating protein TAZ.  wherein, A is ethyl or n-butyl; Ris methyl, &#x2014;CHOH, &#x2014;COCH, &#x2014;CHF, &#x2014;CH(OCH), &#x2014;CHOC(&#x2550;O)CH, styryl or &#x2014;CHOCHSCH; Ris H, Br, &#x2014;COCH, phenyl, pyridin-2-yl, pyridin-3-yl, or styryl; Ris H or methyl; X is CH or N; and P is H or &#x2014;CH(CH)OCHCH.

Pharmaceutical composition for preventing or treating osteoporosis or obesity comprising phenyltetrazole derivative

Provided is a compound having a spiro chiral carbon backbone, a stereoisomer thereof, an enantiomer thereof, an in vivo hydrolysable precursor thereof, or a pharmaceutically acceptable salt thereof. The compound having the spiro chiral carbon backbone has excellent osteoblast differentiation activity, mast cell inhibitory activity, and fatty acid synthesis inhibitory activity in the liver. Therefore, the compound can be expected to play an innovative role in treatment of osteoporosis, fatty liver, and obesity.

Compound with spiro chiral carbon backbone, preparation method thereof, and pharmaceutical composition containing the same

A phamaceutical composition comprising a phenyltetrazole derivative of formula (I) or a pharmaceutical acceptable salt thereof is effective in preventing or treating osteoporosis, obesity, diabetes, or hyperlipidemia, by regulating protein TAZ.  

Growing community of inventors

Seoul, South Korea

Jeong-Ho Hong